Concomitant use of Dopamine agonist Bromocriptine with Glimepride Improves Insulin Sensitivity in Type II Diabetic Patients

Type -2 diabetes mellitus (T2DM) is a complex syndrome originated by a multifactorial pathogenesis. Restoration of a normal glycaemia is very difficult and requires a multiple medication with different mechanismsof action that can be used in combination to produce an additive effect. Bromocriptine (BC) is a sympatholytic D2 dopamine agonist which can be used as an anti-diabetic agent with a novel mechanism of action in combination with a currently used drug glimepiride. Objective: The aim of this work is to study theeffect ofaddition of BC toglimepiride inuncontrolled type 2 diabetic patients treated with glimepiride. Design: we collect the type 2 diabetic patients which treated with glimepiride and not achieved a glycemic control and compare their results with other glimepride-treated group with combination with 1.25 mg BC once daily. Three groups divided randomly: the first group take glimepiride 3mg once daily, the second group takes glimepiride 3 mg once daily plus 1.25 mg of BC once daily, the third group is the control group. A control group comprising healthy, normal glycemic individuals was used for comparison.The effect of BC on glucose homeostasis parameters (e.g. blood glucose level, serum insulin, insulin resistance using the homeostasis model assessment), lipid profile, and dopamine and adiponectin levels are investigated.